CLYM
Climb Bio, Inc.Healthcare·Biotechnology
$10.96
$747M market cap
Revenue
$0.0M
Free Cash Flow
$-30.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered
2-Year Price History
$11.00+30.0%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -15.2 | -15.2 | -13.7 | -14.4 | -14.4 | -0.0 | 109.6 | 0.5 | 68.2 | -154.3% | -- | -- |
| Act | 2025-Q4 | 0.0 | -19.3 | -19.3 | -17.5 | -15.6 | -15.6 | -0.0 | 101.1 | 0.5 | 67.4 | -146.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$10.96
Market Cap$747M
Enterprise Value$638M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-4.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-31.2M
Free Cash Flow$-30.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-150.4%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.8M
Days to Cover2.0
Change (vs Prior)+10.3%
Need at least 2 settlement dates for chart
Employees
Headcount17
Revenue / Employee$0
Gross Profit / Employee$-4,000
Cash Runway
43.8months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
27.0%(+19.3% YoY)
66 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.2%(+1.4% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.5%(+0.5% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $77.4M | $6.85 | +$49K | −$138M | -4.4% | $9.44B |
| MPM BioImpact LLC | $17.8M | $4.00 | −$535K | +$17.8M | -1.8% | $1.29B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $13.1M | $4.35 | −$46K | +$9.1M | -0.2% | $864.93B |
| BRAIDWELL LP | $10.5M | $6.85 | +$10.5M | +$10.5M | -1.8% | $2.63B |
| GREAT POINT PARTNERS LLC | $9.1M | $4.96 | +$2.4M | +$9.1M | -4.6% | $408M |
| MILLENNIUM MANAGEMENT LLC | $8.7M | $5.17 | +$6.7M | +$8.3M | -0.5% | $127.40B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $8.1M | $6.85 | +$8.1M | +$8.1M | — | $4.04T |
| Kynam Capital Management, LP | $6.9M | $1.52 | −$171K | −$299K | +0.5% | $1.58B |
| MARSHALL WACE, LLP | $5.3M | $5.10 | +$3.2M | +$5.3M | +0.6% | $92.71B |
| Affinity Asset Advisors, LLC | $4.8M | $1.22 | −$4.1M | −$5.5M | +0.5% | $1.60B |
| SILVERARC CAPITAL MANAGEMENT, LLC | $4.7M | $6.85 | +$3.9M | +$4.7M | — | $843M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $4.1M | $5.09 | +$0 | +$4.1M | +0.3% | $13.60B |
| ADAR1 Capital Management, LLC | $4.1M | $3.89 | −$5.7M | +$3.3M | +8.3% | $1.64B |
| NAN FUNG TRINITY (HK) Ltd | $2.9M | $1.24 | −$295K | +$2.9M | -0.4% | $911M |
| SPHERA FUNDS MANAGEMENT LTD. | $2.9M | $3.24 | −$3.5M | +$1.2M | -9.9% | $575M |
| BlackRock, Inc.Passive | $2.8M | $4.48 | +$85K | −$13.0M | -0.2% | $5.69T |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $2.7M | $3.27 | −$397K | +$2.4M | -0.6% | $77.14B |
| CITADEL ADVISORS LLC | $2.4M | $3.95 | +$730K | +$1.8M | -0.4% | $138.22B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $2.1M | $4.94 | +$15K | −$2.5M | +2.3% | $1.61T |
| TWO SIGMA INVESTMENTS, LP | $2.1M | $3.30 | −$1.8M | +$380K | -0.9% | $117.03B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.93%
avg per quarter
Holders (ex-self)
-1.99%
excl. this stock
Buyers (this Q)
-0.30%
47 buyers · $0.06B in
Sellers (this Q)
-1.82%
26 sellers · $-0.01B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+5.7%
how holders react when this stock falls
On quiet Qs
-4.8%
−10% to +10% baseline
On rallies (+10%+)
-23.5%
how they react when this stock rises
Holders' portfolio flow this Q
+5.2%
inflows — adds are organic
Sellers' portfolio flow this Q
+17.0%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.3%
Holder mid (any stock)
-3.3%
Holder rally (any stock)
-5.1%
Biggest decreases this quarter
ADAR1 Capital Management, LLC−$5.7Mα+8.3Affinity Asset Advisors, LLC−$4.1Mα+0.5SPHERA FUNDS MANAGEMENT LTD.−$3.5Mα-9.9TWO SIGMA INVESTMENTS, LP−$1.8Mα-0.9RENAISSANCE TECHNOLOGIES LLC−$708Kα+1.2AMERIPRISE FINANCIAL INCexited−$558KMPM BioImpact LLC−$535Kα-1.8Squadron Capital Management LLCexited−$400KSUSQUEHANNA INTERNATIONAL GROUP, LLP−$397Kα-0.6NAN FUNG TRINITY (HK) Ltd−$295Kα-0.4
New buyers this quarter
Top-5 holders · 57.8%
RA CAPITAL MANAGEMENT, L.P.--
MPM BioImpact LLC--
PRICE T ROWE ASSOCIATES INC /MD/--
BRAIDWELL LP--
GREAT POINT PARTNERS LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.11.3MSAMLYN CAPITAL, LLC—Deep Track Capital, LP—Samsara BioCapital, LLC—JANUS HENDERSON GROUP PLC—Boxer Capital, LLC—MPM BioImpact LLC2.6MPRICE T ROWE ASSOCIATES INC /MD/1.9MAffinity Asset Advisors, LLC700KBRAIDWELL LP1.5M
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (7 analysts)$20.008250.0%
Last Year (8 analysts)$18.887230.0%
Current Price$10.96
Analyst Ratings
5
Buy: 5Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$906K
6 txns · 3 insiders · 171,860 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$780K
3 txns · 1 insider · 321,672 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-02-26 | SELL | Thomas Stephen Basil | director | 16,313 | $7.01 | $114K | $1.08M |
| 2026-02-25 | SELL | Thomas Stephen Basil | director | 33,687 | $7.00 | $236K | $1.20M |
| 2026-02-13 | SELL | Thomas Stephen Basil | director | 10,000 | $5.81 | $58K | $1.19M |
| 2026-02-12 | SELL | Thomas Stephen Basil | director | 90,000 | $5.23 | $471K | $1.12M |
| 2026-01-05 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 7,111 | $3.50 | $25K | $11.91M |
| 2025-12-12 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 101,462 | $2.86 | $290K | $9.71M |
| 2025-12-11 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 213,099 | $2.18 | $465K | $7.18M |
| 2025-06-30 | SELL | Brennan Aoife | director, officer: President and CEO | 20,618 | $1.22 | $25K | $59K |
| 2025-06-20 | SELL | Pimblett Emily | officer: SVP, Finance & CAO | 1,242 | $1.24 | $2K | $23K |
Order Flow (FINRA, ~3w lag)
20.5%retail-3.7pp
22.4%dark-0.6pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.